Rebalix
SPDR · sheet of 5 September 2026
SPDR · sheet of 5 September 2026ETF sheet · official issuer and register data
State Street® SPDR® S&P® 400 U.S. Mid Cap UCITS ETF (Dist)
US4D · IE000UYVEVN3 · USD · domicile Ireland
Equity · United States · Mid capSFDR art. 6 (inferred)
Index tracked: S&P MidCap 400<sup>®</sup> Index
- TER
- 0.30%+ trans. 0.01%
- Fund size
- 5.6 bn EUR
- Tracking difference
- —not computable
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Physical (full replication)
- Income
- Distributingquarterly
Launch 23 Jun 2025 · costs from the KID as of 2 Sept 2026 · 401 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 5 Aug 2026
Investment objective The objective of the Fund is to track the equity market performance of mid-sized U.S. companies. The Fund seeks to track the performance of the S&P MidCap 400 Index (the "Index") as closely as possible. The Fund is an index tracking fund (also known as a passively managed fund). Investment policies The Fund invests primarily in securities included in the Index. These securities include the top 400 midsized companies in the U.S. equity market. Although the Index is generally well diversified, to enable the Fund to track the Index…
Performance since series start (in euro) — base 100
24 Jun 2025 → 3 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +18.0% |
| 3 years | series too young |
| 5 years | series too young |
| 10 years | series too young |
| Since series start | +23.9% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 15.22% | 15.22% | — |
| Max drawdown | −9.07% | −9.07% | — |
| Sharpe | 0.94 | 0.94 | — |
| Sortino | 1.41 | 1.41 | — |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · US4D · IE000UYVEVN31
RebalixUS4D · IE000UYVEVN3 · sheet of 5 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · declared by the issuer
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +7.84% | +7.93% | −0.09% |
Distributions · per share, in USD
Frequency: quarterly · last 12 months: 0.2715 USD (0.73% of NAV) · 11 months of history: not a full year · last ex-date 22 Jun 2026
| Year | Payments | Total (USD) |
|---|---|---|
| 2026 | 2 | 0.1469 |
| 2025 | 2 | 0.1246 |
Holdings
Portfolio as declared by the issuer · 31 Aug 2026 · 401 securities · top-10 weight = 7.8%
| Top holdings | Weight |
|---|---|
| 1.0% | |
| 0.9% | |
| 0.9% | |
| 0.8% | |
| 0.8% | |
| 0.8% | |
| 0.7% | |
| 0.7% | |
| 0.7% | |
| 0.7% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
US4D · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 10 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE000UYVEVN3
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE000UYVEVN3
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · US4D · IE000UYVEVN32